Decibel Therapeutics logo
Decibel Therapeutics DBTX

Quarterly report 2023-Q2
added 08-11-2023

report update icon

Decibel Therapeutics Balance Sheet 2011-2026 | DBTX

Annual Balance Sheet Decibel Therapeutics

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-31 M - -27.1 M -18.6 M -11.3 M - - - - - - -

Long Term Debt

19 K - - - - - - - - - - -

Long Term Debt Current

3.57 M - - - - - - - - - - -

Total Non Current Liabilities

- - 523 K 17.5 M 24.8 M - - - - - - -

Total Current Liabilities

22.4 M 20.5 M - - - - - - - - - -

Total Liabilities

41.6 M 42.8 M 230 M 27 M 35.8 M - - - - - - -

Retained Earnings

-278 M -215 M - -123 M -80.7 M - - - - - - -

Total Assets

123 M 184 M 67.3 M 42.8 M 93.3 M - - - - - - -

Cash and Cash Equivalents

34.6 M 36.5 M - - - - - - - - - -

Book Value

81.8 M 142 M -163 M 15.8 M 57.5 M - - - - - - -

Total Shareholders Equity

81.8 M 142 M -54.8 M - - - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Decibel Therapeutics

2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

46 K 9.81 M 10.5 M 11.1 M 11.7 M 12.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

41.1 M 40.6 M 41.6 M 45.5 M 46.4 M 45.7 M 42.8 M 31.1 M 27.5 M 26.8 M 29 M 29 M 29 M 29 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-309 M -291 M -278 M -262 M -246 M -229 M -215 M -202 M -185 M -174 M -163 M -163 M -163 M -163 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

94.4 M 110 M 123 M 142 M 158 M 174 M 184 M 185 M 197 M 207 M 67.3 M 67.3 M 67.3 M 67.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

39.8 M 38.1 M 34.6 M 36.7 M 56.5 M 10.8 M 36.5 M 51.4 M 37.7 M 52.2 M 27.7 M 27.7 M 27.7 M 27.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

53.3 M 69.8 M 81.8 M 96.8 M 112 M 128 M 142 M 154 M 169 M 180 M 38.3 M 38.3 M 38.3 M 38.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

53.3 M 69.8 M 81.8 M 96.8 M 112 M 128 M 142 M 154 M 169 M 180 M -54.8 M -54.8 M -54.8 M -54.8 M -122 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Decibel Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.55 -0.42 % $ 1.06 B canadaCanada
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
AC Immune SA AC Immune SA
ACIU
$ 3.24 3.35 % $ 229 M schweizSchweiz
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 4.14 -1.9 % $ 105 M schweizSchweiz
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.82 4.22 % $ 4.47 M chinaChina
argenx SE argenx SE
ARGX
$ 714.55 1.6 % $ 25 B niderlandNiderland
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 231.26 0.1 % $ 5 B danmarkDanmark
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.4 -5.82 % $ 8.18 B australiaAustralia
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 6.09 0.66 % $ 496 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 6.6 -0.45 % $ 181 M israelIsrael
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
BioCardia BioCardia
BCDA
$ 1.37 7.87 % $ 29 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 11.29 -2.5 % $ 1.01 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.61 1.71 % $ 214 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
BioNTech SE BioNTech SE
BNTX
$ 92.9 2.61 % $ 27.2 B germanyGermany
Aytu BioScience Aytu BioScience
AYTU
$ 2.64 - $ 16.6 M usaUSA
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
$ 2.36 -3.67 % $ 902 K usaUSA
CorMedix CorMedix
CRMD
$ 6.57 0.46 % $ 473 K usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 8.24 2.36 % $ 1.33 B britainBritain
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.5 -0.99 % $ 383 M britainBritain
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany